First Light Asset Management, LLC Alkermes Plc. Transaction History

First Light Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$17.29 - $21.74 $2.13 Million - $2.68 Million	-123,107 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$19.51 - $24.28 $2.05 Million - $2.55 Million	-104,916 Reduced 46.01%	123,107 $2.4 Million
Q2 2019 Aug 14, 2019	BUY	$21.47 - $37.33 $361,962 - $629,346	16,859 Added 7.98%	228,023 $5.14 Million
Q1 2019 May 15, 2019	BUY	$28.4 - $36.49 $1.15 Million - $1.48 Million	40,631 Added 23.83%	211,164 $7.71 Million
Q4 2018 Feb 14, 2019	BUY	$27.94 - $44.61 $3.87 Million - $6.18 Million	138,501 Added 432.38%	170,533 $5.03 Million
Q3 2018 Nov 14, 2018	SELL	$38.6 - $46.12 $9,225 - $11,022	-239 Reduced 0.74%	32,032 $1.36 Million
Q2 2018 Aug 14, 2018	BUY	$40.56 - $51.36 $83,553 - $105,801	2,060 Added 6.82%	32,271 $1.33 Million
Q1 2018 May 15, 2018	BUY	$53.61 - $67.26 $36,347 - $45,602	678 Added 2.3%	30,211 $1.75 Million
Q4 2017 Feb 14, 2018	SELL	$47.69 - $55.39 $26,420 - $30,686	-554 Reduced 1.84%	29,533 $1.62 Million
Q3 2017 Nov 14, 2017	BUY	$49.16 - $54.45 $19,024 - $21,072	387 Added 1.3%	30,087 $1.53 Million
Q2 2017 Aug 14, 2017	BUY	N/A	29,700	29,700 $1.72 Million

362

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.88B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of First Light Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on First Light Asset Management, LLC with notifications on news.